Rani Therapeutics Holdings (RANI) Income from Non-Controlling Interests (2020 - 2026)

Rani Therapeutics Holdings' Income from Non-Controlling Interests history runs 7 years deep, the most recent figure standing at -$982000.0 for Q1 2026.

• On a quarterly basis, Income from Non-Controlling Interests rose 82.06% year-over-year to -$982000.0 in Q1 2026; TTM through Mar 2026 was -$6.8 million, a 72.58% increase from a year earlier, with the FY2025 full-year figure at -$11.3 million, up 57.55% from the prior year.
• Income from Non-Controlling Interests fell to -$982000.0 in Q1 2026 per RANI's latest filing, from $1.2 million in the prior quarter.
• Across five years, Income from Non-Controlling Interests topped out at $1.2 million in Q4 2025 and bottomed at -$9.4 million in Q2 2023.
• The 5-year median for Income from Non-Controlling Interests is -$7.0 million (2023), against an average of -$6.2 million.
• Across the five-year window, Income from Non-Controlling Interests sank 52.09% in 2022 and jumped 118.17% in 2025, its largest moves.
• Year by year, Income from Non-Controlling Interests stood at -$8.6 million in 2022, then grew by 18.69% to -$7.0 million in 2023, then gained by 2.62% to -$6.8 million in 2024, then soared by 118.17% to $1.2 million in 2025, then plunged by 179.77% to -$982000.0 in 2026.
• Per Business Quant, the three latest RANI Income from Non-Controlling Interests figures stand at -$982000.0 (Q1 2026), $1.2 million (Q4 2025), and -$2.5 million (Q3 2025).